SCIENTIFIC PROGRAM

SCIENTIFIC PLANNING COMMITTEE

CO-CHAIRS
Pier Francesco Ferrucci – Istituto Europeo di Oncologia, Milano, IT
Christoph Huber – Association for Cancer Immunotherapy, Mainz, DE
Arlene Sharpe - Harvard Medical School, Boston, MA, USA
Padmanee Sharma - MD Anderson Cancer Center, Houston, TX, USA

COMMITTEE
Mustafa Diken - Johannes Gutenberg University, Mainz, DE
Marina Garassino – University of Chicago, Chicago, IL, USA
Susan Kaech – Salk Institute for Biological Studies, La Jolla, CA, USA
Nir Hacohen, Harvard Medical School, MA, USA
Paola Nisticò – Regina Elena National Cancer Institute, Roma, IT
Pamela Ohashi – University of Toronto, Toronto, CAN
Catherine Sautès-Fridman – Paris Descartes University, Paris, FR
Andrea Schietinger – Sloan Kettering Institute, New York, NY, USA
Özlem Türeci - BioNTech, Mainz, DE
Cassian Yee - MD Anderson Cancer Center, Houston TX, USA
Laurence Zitvogel – Gustave Roussy Institute, Villejuif, FR

LOCAL ORGANISING COMMITTEE
Paola Allavena - Humanitas Research Hospital, Milano
Paolo Ascierto – Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Matteo Bellone – San Raffaele Scientific Institute, Milano
Vincenzo Bronte – Istituto Oncologico Veneto, Padova
Giulia Casorati – San Raffaele Scientific Institute, Milano
Anna Mondino – San Raffaele Scientific Institute, Milano
Vincenzo Russo – San Raffaele Scientific Institute, Milano
Antonio Sica – Humanitas Research Hospital, Milano
Claudio Tripodo – University of Palermo, Palermo
Day 1 - Wednesday, September 20, 2023

1:45 – 2:00 pm  
**Welcome**  
Pier Francesco Ferrucci – Italian Network for Cancer Biotherapy - NIBIT, (Italy)  
Christoph Huber – European Network for Cancer Immunotherapy - ENCI, (Germany)

2:00 – 2:40 pm  
**ENCI-AIRC Lecture**  
Jim Allison – The University of Texas MD Anderson Cancer Centre (USA)  
*Immune Checkpoint Blockade in Cancer Therapy: historical perspective, new opportunities, and prospects for cures*  
Chair: Christoph Huber – European Network for Cancer Immunotherapy - ENCI (Germany)

2:45 – 4:15 pm  
**Session 1: With a little help from my friends: innate immune cells and stromal cells in the tumor microenvironment**  
Chairs: Lisa Coussens, Paola Allavena

2:45 – 3:10 pm  
Lisa Coussens - Knight Cancer Institute (USA)  
*Immune Vulnerabilities in Solid Tumors: Leukocyte Communication Networks Regulate Neoplastic Progression and Response to Therapy*

3:10 – 3:35 pm  
Eric Vivier - Innate Pharma, Paris Saclay Cancer Cluster Marseille (France)  
*Harnessing Innate Immunity in Cancer Therapy*

3:35 – 4:00 pm  
Neta Erez - Tel Aviv University (Israel)  
*Stromal and immune plasticity shape the metastatic microenvironment*

4:00 – 4:15 pm  
Renato Ostuni* - Vita-Salute San Raffaele University (Italy)  
*IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer*

4:15 – 4:45 pm  
Break

4:45 – 6:30 pm  
**Session 2: Deranged T and B cells within the tumor microenvironment**  
Chairs: Andrea Schietinger, Paola Nisticò

4:45 – 5:10 pm  
Catherine Sautès-Fridman - University Paris Cité (France)  
*TLS and B cells in the immunotherapy response*

5:10 – 5:35 pm  
Andrea Schietinger - Sloan Kettering Institute (USA)  
*Intratumoral CD4 T cells: empowering CD8 T cells to eliminate tumors*
5:35 – 6:00 pm  Yifat Merbl - Weizmann Institute (Israel)
Proteasomal profiling: From global views of degradation to novel mechanisms of anti-tumor immunity

6:00 – 6:15 pm  Ludovic Martinet* - Université Toulouse III-Paul Sabatier – INSERM - CNRS (France)
TCR-independent CD137 (4-1BB) signaling promotes CD8+ exhausted T cell proliferation and terminal differentiation

6:15 – 6:30 pm  Simone Park* - University of Pennsylvania (USA)
Nonreciprocal plasticity and divergent development of tissue resident memory and exhausted CD8+ T cells

6:30 – 7:10 pm  William B. Coley Lecture
Tak Wah Mak – University of Toronto (Canada)
Ni Miikana: The Path Forward
Chair: Jill O'Donnell-Tormey - Cancer Research Institute Chief Executive Officer and Director of Scientific Affairs (USA)

7:10 – 8:30 pm  Welcome Reception

*Short talk from proffered abstract
Day 2 - Thursday, September 21, 2023

8:30 – 10:15 am  **Session 3**: The earlier the better: neoadjuvant immunotherapy against cancer  
**Chairs**: Christian Blank, Pier Francesco Ferrucci

8:30 – 8:55 am  **Padmanee Sharma** – MD Anderson Cancer Center (USA)  
*Immune Checkpoint Therapy: Identifying Mechanisms of Response and Resistance*

8:55 – 9:20 am  **Christian Blank** – The Netherlands Cancer Institute (The Netherlands)  
*Neoadjuvant Immunotherapy – next steps towards total personalization*

9:20 – 9.45 am  **Tina Cascone** – MD Anderson Cancer Center (USA)  
*Advances in neoadjuvant and perioperative immunotherapy for lung cancer*

9:45 – 10:00 am  **Giuseppina Arbore*** – Vita-Salute San Raffaele University (Italy)  
*Immune determinants of response to neoadjuvant chemotherapy in esophageal adenocarcinoma*

10:00 – 10:15 am  **Mercedes Machuca-Ostos*** – The Netherlands Cancer Institute (The Netherlands)  
*Early and late T cell dynamics upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma*

10:15 – 10:45 am  **Break**

10:45 – 12:30 pm  **Round table 1**: Harnessing immunotherapy against breast cancer  
**Chairs**: Silvia Formenti, Luis De la Cruz Merino

10:45 – 11:10 am  **Marleen Kok** – The Netherlands Cancer Institute (The Netherlands)  
*Improving immunotherapy for breast cancer patients*

11:10 – 11:35 am  **Fatima Mehta Grigoriou** – Institut Curie (France)  
*Mapping stromal heterogeneity in breast cancer*

11:35 – 12:00 am  **Silvia Formenti** – Weill Cornell Medicine (USA)  
*Adapting radiotherapy to immunotherapy*

12:00 – 12:15 pm  **Nir Ben Chetrit*** – Weill Cornell Medicine (USA)  
*Harnessing innate immunity for immune oncology in breast cancer*

12:15 – 12:30 pm  **Emanuela Romano*** – Institut Curie (France)  
*Tissue resident CD8+ T cell clonal expansion in triple negative breast cancer is associated with response to immunotherapy – exploratory biomarker study from the synergy trial*
12:30 – 2:00 pm  
**Lunch and Poster Session A and Exhibits**

1:00 – 2:00 pm  
**Meet the Editor Session**
Xin (Cindy) Sun – Journal of Experimental Medicine
Paolo Ascierto – Annals of Oncology
Karen Honey – Cancer Immunology Research

2:00 – 2:40 pm  
**Pezcoller Lecture**
Alberto Mantovani – Humanitas Research Institute (Italy)
*Innate Immunity, Inflammation and Cancer: double edged swords*
Chairmen: Enzo Galligioni, President Pezcoller Foundation (Italy)
Mario Paolo Colombo, Istituto Nazionale Tumori (Italy)

2:45 – 4:30 pm  
**Round table 2: Lung cancer at the forefront of cancer immunotherapy**
Chairs: Sergio Quezada, Marina Garassino

2:45 – 3:10 pm  
**Marina Garassino** – University of Chicago (USA)
*Beyond PD-L1 in NSCLC*

3:10 – 3:35 pm  
**Sergio Quezada** – Achilles Therapeutics/ UCL Cancer Institute (UK)
*Targeting Clonal Neoantigens in NSCLC*

3:35 – 4:00 pm  
**Diether Lambrechts** – KU Leuven Center for Cancer Biology (Belgium)
*Unraveling Tumor Immune responses during checkpoint immunotherapy using single-cell and spatial technologies*

4:00 – 4:15 pm  
**Daniela Cerezo-Wallis*** – Yale University (USA)
*Cancer sculpts granulopoiesis to generate tumor-supportive neutrophils*

4:15 – 4:30 pm  
**Edgar Gonzalez-Kozlova*** – Icahn School of Medicine, Mount Sinai (USA)
*Improper priming of tumor antigen-specific human CD4+ T cells leads to a dysfunctional state in immunotherapy-treated cancer patients*

4:30 – 5:00 pm  
**Break**
5:00 – 6:30 pm  **Session 4: Technologies, technologies, technologies: we need more**  
*Chairs: Nir Hacohen, Cassian Yee*

5:00 – 5:25 pm  **Nir Hacohen** – Harvard Medical School (USA)  
*Spatial Organization of the Immune Response in Tumors*

5:25 – 5:50 pm  **Aaron Newman** – Stanford Cancer Institute (USA)  
*Big data approaches for immuno-oncology*

5:50 – 6:15 pm  **Joakim Lundeberg** - KTH Royal Institute of Technology (Sweden)  
*The cancer ecosystems captured by spatially resolved omics*

6:15 – 6:30 pm  **Payal Watchmaker** *– University of California San Francisco (USA)*  
*Primed of synnotch car T cells via CNS-specific antigen allows spatial and temporal regulation of car expression, persistence of T cells in the CNS, resulting in the complete and sustained eradication of aggressive glioblastoma*

6:30 – 6:45 pm  **Arja Ray** *– University of California San Francisco (USA)*  
*Identification of potent effector CD8 T cells in tumors*

*Short talk from proffered abstract*
Day 3 – Friday, September 22, 2023

8:30 – 10:30 am  **Round table 3: How to overcome resistance of poorly sensitive tumors to immunotherapy**  
Chairs: Mustafa Diken, Vincenzo Bronte

8:30 – 8:55 am  Andrea Alimonti – Università della Svizzera Italiana (Switzerland)  
Targeting senescent tumors and immune cells for effective cancer therapy

8:55 – 9:20 am  Vincenzo Bronte – Istituto Oncologico Veneto (Italy)  
The cold immune environment in pancreatic cancer

9:20 – 9:45 am  Özlem Türeci – BioNTech (Germany)  
mRNA-based immunotherapies

9:45 – 10:00 am  Chiara Falcomatà* – Icahn School of Medicine at Mount Sinai (USA)  
Identifying mechanisms of tumor immune composition control in pancreatic cancer subtypes

10:00 – 10:15 am  Tobias Wertheimer* – University of Zurich (Switzerland)  
IL-23 stabilizes an effector Treg program in the tumor microenvironment

10:15 – 10:30 am  Enrico Lugli* – IRCCS Humanitas Research Hospital (Italy)  
NaCl primes CD8+ T cells for enhanced effector function in cancer immunotherapy

10:30 – 11:00 am  Break

11:00 – 12:45 pm  **Round table 4: Melanoma immunotherapy – learning from failure and Success**  
Chairs: Tom Gajewski, Pier Francesco Ferrucci

11:00 – 11:25 am  Tom Gajewski – The University of Chicago (USA)  
Improving immunotherapy efficacy by understanding mechanisms of resistance

11:25 – 11:50 am  Paolo Ascierto – National Tumour Institute “Fondazione G. Pascale” (Italy)  
Combination strategy to overcome resistance

11:50 – 12:15 pm  Jeffrey Weber – NYU Langone New York (USA)  
Neo-antigen vaccines with checkpoint inhibition: a novel adjuvant strategy for melanoma and other cancers.

12:15 – 12:30 pm  Clea Dziagwa* – University of Liège (Belgium)  
KEOPS complex links TRNA modification to T cell activation in melanoma

12:30 – 12:45 pm  Joanna Pozniak* – VIB KU Leuven (Belgium)  
The increasing complexity of the melanoma transcriptomic landscape and its changes under immunotherapy
12:45 – 2:00 pm  Lunch and Poster Session B and Exhibits

2:00 – 4:10 pm  Session 5: Metabolic barriers to cancer immunotherapy
Chairs: Guido Kroemer, Vincenzo Russo

2:00 – 2:25 pm  Guido Kroemer – Universitè de Paris (France)
Improving the cancer-immune crosstalk by caloric restriction mimetics

2:25 – 2:50 pm  Susan Kaech – Salk Institute for Biological Studies (USA)
Nutritional influence on T cell exhaustion

2:50 – 3:15 pm  Antonio Sica – University of Eastern Piedmont (Italy)
Metabolic dysregulation of myelopoiesis in cancer

3:15 – 3:40 pm  Greg Delgoffe – University of Pittsburgh (USA)
Metabolic inputs and outputs of exhausted T cells in cancer

3:40 – 3:55 pm  Teresa Manzo* – European Institute of Oncology (Italy)
Linoleic acid potentiates CD8+ T cell metabolic fitness and anti-tumor immunity

4:00 – 4:30 pm  Break

4:30 – 6:25 pm  Session 6: Determinants of response to immunotherapy
Chairs: Arlene Sharpe, Antonio Sica

4:30 – 4:55 pm  Arlene Sharpe – Harvard Medical School (USA)
Overcoming microbiome-related resistance to PD-1/PD-L1 cancer immunotherapy

4:55 – 5:20 pm  Paola Nisticò – IFO Regina Elena National Cancer Institute (Italy)
hMENA isoforms as architects of lung tumor immune microenvironment and determinants of immunotherapy response

5:20 – 5:45 pm  Alessandra Castiglioni – Genentech (USA)
Anti-PD-L1 + anti-TGFβ combination therapy expands stem cell-like CD8 T cells in immune-excluded tumors

5:45 – 6:00 pm  Lucas Blanchard* – Rockefeller University (USA)
Overcoming the inhibitory FCYRIIB barrier unlocks FC-dependent activity of human anti-CTLA-4 antibodies
6:00 – 6:15 pm  
**Jyh Liang Hor** – National Institutes of Health (USA)  
*PD-1/CDC1 axis regulates stem-like CD8+ T cell differentiation in the tumor draining lymph node*

6:15 – 6:30 pm  
**Mike Curran** – MD Anderson Cancer Center (USA)  
*Cytotoxic PD-L1/PL-L2 dual-specific antibodies effectively treat both immune “hot” and “cold” cancers*

*Short talk from proffered abstract*
**Day 4 – Saturday, September 23, 2023**

**8:30 – 10:40 pm**  
**Session 7: Bang on target: modulating the microbiota to improve cancer immunotherapy**  
*Chairs: Laurence Zitvogel, Matteo Bellone*

- **8:30 – 8:55 am**  
  Florencia McAllister – MD Anderson Cancer Center (USA)  
  *Tumor resident microbes influencing immune responses*

- **8:55 – 9:20 am**  
  Laurence Zitvogel – Gustave Roussy Cancer Campus (France)  
  *Microbiota-dependent emigration of enterotropic T cells to tumors*

- **9:20 – 9:45 am**  
  Kathy McCoy – University of Calgary (Canada)  
  *Identifying microbes and metabolites that modulate cancer immunotherapy to translate discovery to treatment*

- **9:45 – 10:10 am**  
  Matteo Bellone – IRCCS San Raffaele Hospital (Italy)  
  *Impact of diet and microbiota on immunotherapy for plasma cell dyscrasias*

- **10:10 – 10:25 am**  
  Martina Molgora* – Washington University School of Medicine (USA)  
  *Lack of TREM2 during anti-PD1 therapy reprograms intestinal macrophages and microbiota to enhance tumor rejection*

- **10:25 – 10:40 am**  
  Vincent Rosa* – Columbia University (USA)  
  *Engineered probiotics direct the antigen-specificity of CAR-T cells in situ for broad tumor targeting*

**10:40 – 11:10**  
*Break*

**11:10 – 1:20 pm**  
**Session 8: Cellular therapies: arming immune cells**  
*Chairs: Giulia Casorati, Anna Mondino*

- **11:00 – 11:25 am**  
  George Coukos – University of Lausanne (Switzerland)  
  *TIL therapy opportunities for solid tumors*

- **11:25 – 11:50 am**  
  Cassian Yee – University of Texas (USA)  
  *TCR-based Tumor Agnostic Cell Therapy*

- **11:50 – 12:15 pm**  
  Chiara Bonini – Vita-Salute San Raffaele University (Italy)  
  *Multiple genome editing for cancer immunotherapy with engineered lymphocytes*

- **12:15 – 12:40 pm**  
  Gianpietro Dotti – University of North Carolina Lineberger Comprehensive Cancer Center (USA)  
  *CAR-T cells next generation*
12:40 – 1:05 am  **Max Topp** - University of Würzburg (Germany)
*TBD*

1:05 – 1:20 pm  **Lakshmi Balagopalan*** – National Cancer Institute (USA)
*Generation of novel anti-tumor chimeric antigen receptors incorporating T cell signaling proteins*

1:20 – 2:00 pm  **AACR Keynote Lecture**
**Toni Ribas** - UCLA (USA)
*How Does PD-1 Blockade Immunotherapy for Melanoma Work?*

2:00 pm  **Closing remarks and meeting ends**
**Pier Francesco Ferrucci**

*Short talk from proffered abstract*